Meeting
2021 Genitourinary Cancers Symposium
Prevalence of oligoprogression in metastatic hormone-resistant prostate cancer patients on androgen targeted therapies: Could targeted radiotherapy improve patient outcomes?
Authors
Priyanka Patel
The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, United Kingdom
Priyanka Patel , Nina Tunariu , Alison Tree
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 110)
DOI
10.1200/JCO.2021.39.6_suppl.110
Abstract #
110
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Statin type and survival of patients with metastatic castrate-resistant prostate cancer receiving abiraterone and enzalutamide: A nationwide retrospective cohort study.
First Author: Harrison Yoon
Poster
2020 Genitourinary Cancers Symposium
Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1).
First Author: Antonin Broyelle
Poster
2020 Genitourinary Cancers Symposium
The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Shabbir M.H. Alibhai
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters